Document is current
Any future updates will be listed below
-
Authors
Hanel, Walter
Lata, Pushpa
Youssef, Youssef
Tran, Ha
Tsyba, Liudmyla
Sehgal, Lalit
Blaser, Bradley W.
Huszar, Dennis
Helmig-Mason, JoBeth
Zhang, Liwen
Schrock, Morgan S.
Summers, Matthew K.
Chan, Wing Keung
Prouty, Alexander
Mundy-Bosse, Bethany L.
Chen-Kiang, Selina
Danilov, Alexey V.
Maddocks, Kami
Baiocchi, Robert A.
Alinari, Lapo
-
Funding
Funding for this research was provided by:
National Institutes of Health (2K12CA133250-06A1, P01 CA214272, P01 CA214272, P01 CA214272)
Conquer Cancer Foundation (2020YIA-6689186701)
American Brain Tumor Association Basic Research Fellowship sponsored by an Anonymous Corporate Partner
Pelotonia IDEA grant
- License Information
-
More Information
Article History
Received: 24 March 2022
Accepted: 25 May 2022
First Online: 13 July 2022
Declarations
:
: Primary MCL samples were obtained following written informed consent under a protocol approved by the Institutional Review Board of The Ohio State University in accordance with the Declaration of Helsinki. All animal studies were approved by the OSU Institutional Animal Care and Use Committee.
: Not applicable.
: D.H. was an employee of, and stockholder in, Takeda Pharmaceutical Company Limited while engaged in the research project. A.V.D. has received consulting fees from Abbvie, AstraZeneca, BeiGene, Genentech, Pharmacyclics and TG Therapeutics and has ongoing research funding from AstraZeneca, Bayer Oncology, Bristol Meyers Squibb, MEI Pharma, SecuraBio, TG Therapeutics and Takeda Oncology.
